← Eichor
Condition: Castration Sensitive Prostate Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Castration Sensitive Prostate Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05956639Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT05919329PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
Phase N/A · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07691697An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic H
Phase 2 · 67 location(s) · Novartis Pharmaceuticals · NCT06991556FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer,
Phase 2 · 6 location(s) · Northwestern University · NCT06244004Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06350825The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer
Phase N/A · 2 location(s) · Uppsala University · NCT06446401Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
NA · 1 location(s) · Umeå University · NCT04612907A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Phase 2 · 50 location(s) · Astellas Pharma Global Development, Inc. · NCT07005154Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04734730Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07290270Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
NA · 1 location(s) · Qilu Hospital of Shandong University · NCT07172685Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Canc
Phase N/A · 26 location(s) · AstraZeneca · NCT07052578Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic
Phase 3 · 26 location(s) · Nick Beije · NCT07260435Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Phase 3 · 1 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT05352178Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivati
Phase 2 · 3 location(s) · Mayo Clinic · NCT06378866This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W
Phase 3 · 341 location(s) · Pfizer · NCT07028853Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06177015Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT06305598Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
Phase 2 · 12 location(s) · Fundacion Oncosur · NCT06582628A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01AD
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT04633252Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
NA · 1 location(s) · Paul Viscuse · NCT06429813A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
Phase 1 · 1 location(s) · Astellas Pharma Global Development, Inc. · NCT07339267PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
Phase 2 · 1 location(s) · University of Miami · NCT06392295CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer
NA · 1 location(s) · RenJi Hospital · NCT06306612Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
Phase 3 · 25 location(s) · UNICANCER · NCT06496581Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inh
Phase 1 · 16 location(s) · Amgen · NCT07140900ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Phase 3 · 32 location(s) · Karolinska Institutet · NCT03903835A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Phase 1 · 15 location(s) · Janssen Research & Development, LLC · NCT05818683An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
Phase N/A · 1 location(s) · Bayer · NCT06334120
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.